Fortress Biotech Crecimiento futuro

Future controles de criterios 5/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Fortress Biotech de 105% y 37.6% respectivamente, mientras que el BPA crecerá en un 101.5% al año.

Información clave

105.0%

Tasa de crecimiento de los beneficios

101.53%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	22.6%
Tasa de crecimiento de los ingresos	37.6%
Rentabilidad financiera futura	n/a
Cobertura de analistas	Low
Última actualización	13 Jan 2026

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Investors Still Aren't Entirely Convinced By Fortress Biotech, Inc.'s (NASDAQ:FBIO) Revenues Despite 27% Price Jump

Dec 16

Revenues Working Against Fortress Biotech, Inc.'s (NASDAQ:FBIO) Share Price Following 26% Dive

Oct 05

Fortress Biotech, Inc. (NASDAQ:FBIO) Could Be Riskier Than It Looks

Aug 17

FDA Approval Will Open $1 Billion Dermatology Market

Jul 06 Emrosi's successful launch and growing market adoption are expected to drive significant revenue growth, improved operating leverage, and expanding net margins.

Benign Growth For Fortress Biotech, Inc. (NASDAQ:FBIO) Underpins Its Share Price

Mar 11

Fortress Biotech, Inc.'s (NASDAQ:FBIO) Shares Bounce 36% But Its Business Still Trails The Industry

Oct 29

Fortress Biotech, Inc. (NASDAQ:FBIO) Held Back By Insufficient Growth Even After Shares Climb 54%

Jul 26

There's No Escaping Fortress Biotech, Inc.'s (NASDAQ:FBIO) Muted Revenues Despite A 99% Share Price Rise

Dec 29

There Is A Reason Fortress Biotech, Inc.'s (NASDAQ:FBIO) Price Is Undemanding

Aug 18

Fortress to get NIH funding for trial of Triplex vaccine to prevent CMV in liver transplant patients

Aug 11

David Jin is the new finance chief of Fortress Biotech

Jul 22

Previsiones de crecimiento de beneficios e ingresos

NasdaqCM:FBIO - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2027	145	63	N/A	N/A	1
12/31/2026	110	1	N/A	N/A	2
12/31/2025	73	11	N/A	N/A	2
9/30/2025	62	-5	-81	-66	N/A
6/30/2025	59	-24	-95	-80	N/A
3/31/2025	58	-51	-89	-74	N/A
12/31/2024	58	-56	-95	-80	N/A
9/30/2024	82	-58	-102	-102	N/A
6/30/2024	83	-49	-100	-99	N/A
3/31/2024	85	-63	-113	-110	N/A
12/31/2023	85	-69	-136	-128	N/A
9/30/2023	62	-86	-150	-141	N/A
6/30/2023	63	-104	-176	-168	N/A
3/31/2023	64	-100	-182	-176	N/A
12/31/2022	76	-95	-202	-179	N/A
9/30/2022	78	-97	-196	-170	N/A
6/30/2022	82	-93	-181	-149	N/A
3/31/2022	81	-74	-179	-142	N/A
12/31/2021	69	-65	-133	-117	N/A
9/30/2021	64	-38	-113	-98	N/A
6/30/2021	53	-33	-110	-101	N/A
3/31/2021	44	-43	-89	-83	N/A
12/31/2020	46	-47	-91	-84	N/A
9/30/2020	43	-57	-99	-88	N/A
6/30/2020	43	-54	-92	-81	N/A
3/31/2020	43	-54	-102	-92	N/A
12/31/2019	37	-40	-104	-95	N/A
9/30/2019	34	-45	-98	-92	N/A
6/30/2019	30	-51	N/A	-101	N/A
3/31/2019	27	-53	N/A	-96	N/A
12/31/2018	27	-73	N/A	-99	N/A
9/30/2018	-107	-61	N/A	-98	N/A
6/30/2018	-65	-69	N/A	-98	N/A
3/31/2018	-22	-72	N/A	-98	N/A
12/31/2017	17	-65	N/A	-81	N/A
9/30/2017	155	-74	N/A	-78	N/A
6/30/2017	109	-60	N/A	-62	N/A
3/31/2017	61	-55	N/A	-46	N/A
12/31/2016	16	-55	N/A	-46	N/A
9/30/2016	4	-50	N/A	-35	N/A
6/30/2016	3	-55	N/A	-31	N/A
3/31/2016	1	-49	N/A	-30	N/A
12/31/2015	1	-48	N/A	-20	N/A
9/30/2015	1	-40	N/A	-17	N/A
6/30/2015	1	-27	N/A	-14	N/A
3/31/2015	1	-25	N/A	-12	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que FBIO sea rentable en los próximos 3 años, lo que se considera un crecimiento más rápido que la tasa de ahorro (3.3%).

Beneficios vs. Mercado: Se prevé que FBIO sea rentable en los próximos 3 años, lo que se considera un crecimiento del mercado superior a la media.

Beneficios de alto crecimiento: Se espera que FBIO sea rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (37.6% al año) de FBIO crezcan más rápidamente que los del mercado US (10.6% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos (37.6% al año) de FBIO crezcan más rápidamente que un 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de FBIO se prevé que sea elevada dentro de 3 años.

Descubre empresas en crecimiento

Análisis de la empresa y estado de los datos financieros

Datos	Última actualización (huso horario UTC)
Análisis de la empresa	2026/01/27 01:01
Precio de las acciones al final del día	2026/01/27 00:00
Beneficios	2025/09/30
Ingresos anuales	2024/12/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

Paquete	Datos	Marco temporal	Ejemplo Fuente EE.UU. ^*
Finanzas de la empresa	10 años	Cuenta de resultados Estado de tesorería Balance	Formulario SEC 10-K Formulario SEC 10-Q
Estimaciones del consenso de analistas	+3 años	Previsiones financieras Objetivos de precios de los analistas	Informes de análisis Blue Matrix
Precios de mercado	30 años	Precios de las acciones Dividendos, escisiones y acciones	Datos de mercado ICE Formulario S-1 de la SEC
Propiedad	10 años	Accionistas principales Información privilegiada	Formulario SEC 4 Formulario SEC 13D
Gestión	10 años	Equipo directivo Consejo de Administración	Formulario SEC 10-K Formulario SEC DEF 14A
Principales avances	10 años	Anuncios de empresas	Formulario SEC 8-K

^* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

Fortress Biotech, Inc. está cubierta por 13 analistas. 2 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

Analista	Institución
Scott Henry	Alliance Global Partners
Stephen V. Byrne	BofA Global Research
Mayank Mamtani	B. Riley Securities, Inc.

Fortress Biotech Crecimiento futuro

Future controles de criterios 5/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Forecast to breakeven in 2026

Consensus revenue estimates decrease by 11%, EPS upgraded

Price target increased by 7.5% to US$10.75

Consensus revenue estimates fall by 19%

Price target decreased by 33% to US$10.00

Price target increased by 40% to US$21.00

Recent updates

Forecast to breakeven in 2026

Fortress Biotech and Cyprium Therapeutics Announce U.S. Fda Approval of Zycubo

Investors Still Aren't Entirely Convinced By Fortress Biotech, Inc.'s (NASDAQ:FBIO) Revenues Despite 27% Price Jump

Fortress Biotech, Inc. and Cyprium Therapeutics, Inc. Announce FDA Acceptance of CUTX-101 NDA Resubmission

Consensus revenue estimates decrease by 11%, EPS upgraded

Price target increased by 7.5% to US$10.75

Third quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind

Fortress Biotech, Inc. to Report Q3, 2025 Results on Nov 12, 2025

Revenues Working Against Fortress Biotech, Inc.'s (NASDAQ:FBIO) Share Price Following 26% Dive

Fortress Biotech and Cyprium Therapeutics Announce an Update on the NDA for CUTX-101

New minor risk - Share price stability

Consensus revenue estimates fall by 19%

New major risk - Revenue and earnings growth

Fortress Biotech, Inc. (NASDAQ:FBIO) Could Be Riskier Than It Looks

Second quarter 2025 earnings: EPS and revenues exceed analyst expectations

Fortress Biotech, Inc. to Report Q2, 2025 Results on Aug 12, 2025

FDA Approval Will Open $1 Billion Dermatology Market

Fortress Biotech, Inc.(NasdaqCM:FBIO) dropped from Russell 3000E Growth Index

Sun Pharmaceutical Industries Limited (NSEI:SUNPHARMA) completed the acquisition of Checkpoint Therapeutics, Inc. (NasdaqCM:CKPT) from Fortress Biotech, Inc., Armistice Capital Master Fund Ltd., managed by Armistice Capital LLC and others.

Price target decreased by 33% to US$10.00

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Insufficient new directors

Fortress Biotech, Inc., Annual General Meeting, Jun 17, 2025

Fortress Biotech, Inc. Announces Resignation of Lucy Lu, M.D as from the Board of Directors

Price target increased by 40% to US$21.00

Consensus revenue estimates fall by 46%

Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Benign Growth For Fortress Biotech, Inc. (NASDAQ:FBIO) Underpins Its Share Price

Fortress Biotech, Inc. and Helocyte, Inc. Announce First Patient Dosed in Phase 2 Clinical Trial of Triplex Vaccination in Stem Cell Donors to Reduce CMV Events in Recipients of HSCT

Price target increased by 7.1% to US$15.00

Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Acceptance and Priority Review of NDA for CUTX-101 for Treatment of Menkes Disease

Forecast to breakeven in 2026

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Fortress Biotech, Inc.'s (NASDAQ:FBIO) Shares Bounce 36% But Its Business Still Trails The Industry

Consensus revenue estimates fall by 24%

Fortress Biotech, Inc. has completed a Follow-on Equity Offering in the amount of $6.5 million.

Fortress Biotech, Inc. announced that it has received $1.500001 million in funding

Fortress Biotech, Inc. has completed a Follow-on Equity Offering in the amount of $128 million.

Consensus revenue estimates increase by 41%

Second quarter 2024 earnings: EPS exceeds analyst expectations

Price target increased by 7.7% to US$14.00

New minor risk - Share price stability

Fortress Biotech, Inc. (NASDAQ:FBIO) Held Back By Insufficient Growth Even After Shares Climb 54%

Fortress Biotech, Inc. announced that it expects to receive $50 million in funding

Consensus EPS estimates fall by 93%, revenue upgraded

New major risk - Negative shareholders equity

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Fortress Biotech Announces First Patient Dosed in Multi-Center Phase 2 Study of Triplex for Control of CMV in Patients Undergoing Liver Transplantation

New major risk - Revenue and earnings growth

Fortress Biotech, Inc., Annual General Meeting, May 23, 2024

New minor risk - Profitability

No longer forecast to breakeven

Full year 2023 earnings: EPS and revenues exceed analyst expectations

New minor risk - Profitability

Eric Rowinsky Announces Not Stand for Re-Election to the Board of Fortress Biotech, Inc

Executive Chairman recently bought US$119k worth of stock

There's No Escaping Fortress Biotech, Inc.'s (NASDAQ:FBIO) Muted Revenues Despite A 99% Share Price Rise

Price target increased by 27% to US$67.50

Price target decreased by 14% to US$50.00

Forecast to breakeven in 2024

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

New major risk - Shareholder dilution

Fortress Biotech, Inc. has completed a Composite Units Offering.

Journey Medical Corporation Announces Data from Bioavailability Study of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 Mg) Vs. Solodyn (Minocycline Hydrochine Hydrochloride Extended-Release Tablets, 105 Mg)

New major risk - Share price stability

Fortress Biotech Announces Reverse Stock Split to Regain Compliance

Price target decreased by 8.1% to US$3.55

Consensus revenue estimates fall by 20%

There Is A Reason Fortress Biotech, Inc.'s (NASDAQ:FBIO) Price Is Undemanding